| BackgroundThere exists a tendency that attack rate and the death rate of asthma show increasing in the world, therefore many studies on the mechanism of asthma are carried out deeply. The data from these researches indicate that asthma was referred to the airway chronic inflammation. This airway chronic inflammation induce increase of airway hyperresponsiveness and in above-mentioned course mediators of inflammation and cytokine is very important effective , the cytokine such as ECP,MBP,LTS,TXA2,PAF, can lead to IAR and LAR.Progressing with the study on the mechanism of asthma, especially on the airway chronic inflammation, the therapy on the asthma has obtained great advancement. GINA, produced by WHO and American state-maintained health center , as an important guidance is used in prevention and cure of asthma. Mediators of inflammation suppressive agent and receptor antagonist is criticality for asthma treatment. Among the total LTS receptor antagonist recommend to apply by GINA, it is hope to become a new medicine for curing asthma by TXA2 receptor antagonist and PAF receptor antagonist.PurposeIn this study, the effect of the budesonide and the thromboxane A2 receptor antagonist (Seratrodast) on EOS,IL-10,lung function, CD4/CD8 and NK cell in asthma was discussed.MethodA randomized clinical study was carried out in 32 bronchial asthmatic patients, in whom get rid of other cardiopulmonary diseases , immune system diseases, hematological system diseases, and not used cortisone, The diagnostic standard of respiratory of Chinese medical association in 2003, and they were randomized into 2 groups. The treatment group was performed antibiotics, aminophylline,β2-acceptor energizer and 200ug of Budesonide Aerosol; The other group, therapy group give 80mg Seratrodast in that base. time of therapy is six months. Before and after treatment, peripheral blood (3ml) was obtained from the patients. And the blood inspection was carried out for checking the change of EOS,IL-10,CD4+,CD8+,CD4+/CD8+,NKcell,FEV1/FVC and PEF.ResultsThe main results obtained in this study are as follows.1. The level of IL-10 is low before treatment, there is a significant difference between before and after treatment of two groups in statistics (P<0.05); the level in the treatment group was significant higher than that in the control group (P<0.05).2. Compared to before treatment, the level of FEV1/FVC%,PEF increases remarkably, it has a significant difference in statistics (P<0.05). the level in the treatment group was obvious higher than that in the control group (P<0.05). 3. The level of CD4,CD4/CD8 and NK rate decreased after treatment in two group, there is a significant difference between them(P<0.05),the decreased level in the treatment group was obvious difference than that in the control group in statistics (P<0.05).4. The level of EOS declined after treatment in two group, there is a significant difference between them(P<0.05),the declined level in the treatment group was obvious difference than that in the control group in statistics (P<0.05).5. The rate of hospitalization rate again between two group has remarkable difference in statistics in six months (P<0.05).ConclusionsThe main conclusions obtained in this study are as follows:1. Seratrodast, a thromboxane A2 receptor antagonist , has the effect on asthma. SD and hormone can efficiently control attack of asthma, but there exists no effect by only SD.2. budesonide ally thromboxane A2 receptor antagonist can inhibit the releasing of much mediators of inflammation and cytokine , promote IL-10 and improve pulmonary function ,profit to long-term stable of asthma .
|
PDF Full Text Request